Background: Colorectal cancer (CRC) is the fourth deadliest cancer, with approximately 900,000 deaths annually. CRC is a multifactorial disease in which a set of factors, including environmental, hereditary, and genetic factors, are integrated into cancer development. Studies have suggested an association between hereditary antigens in the human blood group system and the risk of different cancers. This study aimed to evaluate the relationship between blood groups and CRC risk.
Methods: A record-based retrospective study was performed between January 2017 and August 2021. This study targeted patients diagnosed with CRC during the study period. Data of patients who agreed to participate were collected using a pre-structured checklist. The extracted data included patients' demographic blood groups and risk factors, including history of inflammatory bowel disease or CRC.
Results: A total of 199 patients, aged 22 to 96 years (mean age: 61.6 ± 14.7 years), were included. The blood groups of 101 (50.8%), 59 (29.6%), 26 (13.1%), and 13 (6.5%) patients were O, A, B, and AB, respectively. Colon cancer was the most frequently reported cancer (155/199, 77.9%) across all blood groups and showed the highest frequency among patients with blood group O (74/155, 47.7%), without statistical significance (P = 0.111).
Conclusion: Our study showed a statistically significant relationship between AB and non-O blood types and colon cancer compared to the O blood group.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993432 | PMC |
| http://dx.doi.org/10.14740/jocmr4691 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug Development.
Alzheimers Dement
December 2024
National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.
Background: Cilostazol, a selective type-3 phosphodiesterase inhibitor, ameliorates β-amyloid accumulation by facilitating intramural periarterial drainage.
Method: Patients with mild cognitive impairment were registered in the COMCID study, an investigator-initiated, double-blinded, multi-center, phase-II clinical trial. The primary endpoint was the Mini-Mental State Examination score.
Drug Development.
Alzheimers Dement
December 2024
Ahmadu Bello University Zaria, Zaria, Kaduna, Nigeria.
Background: Studies suggest a potential link between stroke and Alzheimer's disease wherein stroke may serve as a trigger for the onset or acceleration of Alzheimer's pathogenesis as damage to the brain's blood vessels may lead to the accumulation of amyloid beta protein which is a hallmark of Alzheimer's disease. Recent research has shown that stroke treatment may hold the key to treating Alzheimer's disease. The anti-inflammatory potentials of Cholinergic signaling are a novel therapeutic target in memory decline associated with Alzheimer's.
View Article and Find Full Text PDFBackground: Previously, we demonstrated therapeutic benefits following intraperitoneal delivery of the TGR5 agonist HY209 in 5xFAD, a transgenic mouse model of Alzheimer's Disease (AD). Given the desirability of a more acceptable administration route for prolonged AD treatment, we assessed the efficacy of HY209 via oral delivery. This study aims to elucidate the therapeutic potential of NuCerin, an oral formulation of HY209, in the aforementioned AD model, while simultaneously identifying potential blood biomarkers indicative of NuCerin's therapeutic action.
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
University of Southern California, Los Angeles, CA, USA.
Background: Blood pressure (BP) management is an accessible therapeutic target for dementia prevention. BP variability (BPV) is a newer aspect of BP control recently associated with cognitive decline, dementia and Alzheimer's disease (AD), independent of traditionally targeted mean BP levels. Most of this work has relied on largely non-Hispanic White study samples in observational cohorts.
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
Afe-Babalola University, Ado-Ekiti, Ekiti State, Nigeria.
Background: Diabetic conditions are associated with alterations in brain functions like memory deficits through processes like synaptic dysfunction in the hippocampus. Administering a combination of silver nanonaringenin and vitamin E appears promising since they are known to prevent diabetes and memory deficits in previous studies, and nanoformulation of naringenin may be one way to improve delivery and bioavailability of naringenin in the brain. This study investigated the effects of co-administering silver nanonaringenin and vitamin E against memory deficits and synaptic dysfunction in the hippocampus of a mice model of high-fat diet and streptozotocin (HS).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!